Leerink analyst David Risinger initiated coverage of Tenax Therapeutics (TENX) with an Outperform rating and $16 price target The firm expects shares to rise as the investment community comes to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...